We gratefully acknowledge generous funding sources including the Medical Research Council (G0901539), Wellcome Trust (082,868), US National Institutes of Health (P50-DE016215, R01-DE08559, R01-DE016148, R01-DE014581, U01-DE018993 and U01-DE20057), the Healing Foundation and the Manchester NIHR Biomedical Research Centre
By starting with a low dose, we help minimize side effects and let your body adapt
Faial Miyara joins as Chief Business Officer, leading global business development 20+ yrs oncology BD experience (Pfizer, Ipsen, IO Biotech) Jim Ziegler joins as Chief China IND Tracker (Jul 27Aug 1) 15 innovative drugs received their first IND clearances in China last week
Phosphatidylserine on blood cells and endothelial cells contributes to the hypercoagulable state in cirrhosis
Like we said, peptides are just one piece of a larger puzzle in regards to muscle growth, recovery, and overall metabolic health
The emergence of dual agonists like Tirzepatide shows how combining pathways can significantly enhance outcomes, raising the bar for both efficacy and patient results